Form 4: RA Capital Sells AN2 Therapeutics Shares

RA Capital Management and related entities sold shares of AN2 Therapeutics at an average price of $1.08.

Summary

• RA Capital Management, L.P., along with related entities including RA Capital Healthcare Fund, L.P., RA Capital Nexus Fund II, L.P., Peter Kolchinsky, and Rajeev Shah, filed a Form 4.
• The filing reports the sale of AN2 Therapeutics, Inc. common stock on August 9, 2024.
• 3,410,335 shares were sold at a weighted average price of $1.08.
• An additional 114,759 shares were sold at the same weighted average price of $1.08.
• The sales resulted in a decrease in direct holdings and a change in indirect beneficial ownership.
• The reporting persons disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interest therein.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the document itself is simply a report of transactions, the sale of shares by a major holder like RA Capital could be interpreted negatively by the market.

Negatives

• RA Capital Management reduced its stake in AN2 Therapeutics through the sale of shares.

Risks

• The sale of shares by a major shareholder like RA Capital could create downward pressure on the stock price.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders or major shareholders of a publicly traded company buy or sell shares. These filings are closely watched by investors for insights into the sentiment and actions of those with privileged information about the company.

Stakeholder Impact

• The sale of shares could potentially impact shareholder value if it leads to a decrease in the stock price.
• The impact on other stakeholders is likely to be minimal unless the share sale signals a larger strategic shift.

Key Dates